Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae

Nicole E Scangarella-Oman, Mohammad Hossain, Paula B Dixon, Karen Ingraham, Sharon Min, Courtney A Tiffany, Caroline R Perry, Aparna Raychaudhuri, Etienne F Dumont, Jianzhong Huang, Edward W Hook 3rd, Linda A Miller, Nicole E Scangarella-Oman, Mohammad Hossain, Paula B Dixon, Karen Ingraham, Sharon Min, Courtney A Tiffany, Caroline R Perry, Aparna Raychaudhuri, Etienne F Dumont, Jianzhong Huang, Edward W Hook 3rd, Linda A Miller

Abstract

We evaluated microbiological correlates for the successful treatment of Neisseria gonorrhoeae isolates from a phase 2 study of gepotidacin, a novel triazaacenaphthylene antibacterial, for therapy of uncomplicated urogenital gonorrhea. Culture, susceptibility testing, genotypic characterization, and frequency of resistance (FoR) were performed for selected isolates. Microbiological success was defined as culture-confirmed eradication of N. gonorrhoeae Against 69 baseline urogenital isolates, gepotidacin MICs ranged from ≤0.06 to 1 µg/ml (MIC90 = 0.5 µg/ml). For gepotidacin, the ratio of the area under the free-drug concentration-time curve to the MIC (fAUC/MIC) was associated with therapeutic success. Success was 100% (61/61) at fAUC/MICs of ≥48 and decreased to 63% (5/8) for fAUC/MICs of ≤25. All 3 isolates from microbiological failures were ciprofloxacin resistant, had a baseline gepotidacin MIC of 1 µg/ml, and carried a preexisting ParC D86N mutation, a critical residue for gepotidacin binding. In a test-of-cure analysis, the resistance to gepotidacin emerged in 2 isolates (MICs increased ≥32-fold) with additional GyrA A92T mutations, also implicated in gepotidacin binding. Test-of-cure isolates had the same sequence type as the corresponding baseline isolates. For 5 selected baseline isolates, all carrying a ParC D86N mutation, the in vitro FoR to gepotidacin was low (10-9 to 10-10); the resistant mutants had the same A92T mutation as the 2 isolates in which resistance emerged. Five participants with isolates harboring the ParC D86N mutation were treatment successes. In summary, fAUC/MICs of ≥48 predicted 100% microbiological success, including 3 isolates with the ParC D86N mutation (fAUC/MICs ≥ 97). Pharmacokinetic/pharmacodynamic determinations may help to evaluate new therapies for gonorrhea; further study of gepotidacin is warranted. (This study has been registered at ClinicalTrials.gov under identifier NCT02294682.).

Keywords: Neisseria gonorrhoeae; microbiology; urogenital gonorrhea.

Copyright © 2018 Scangarella-Oman et al.

Figures

FIG 1
FIG 1
Frequency distribution of gepotidacin MICs against baseline urogenital N. gonorrhoeae isolates (N = 69).

References

    1. Centers for Disease Control and Prevention. 2017. Reported STDs in the United States, 2016. High burden of STDs threaten millions of Americans. Centers for Disease Control and Prevention, Atlanta, GA. .
    1. Centers for Disease Control and Prevention. 2017. Sexually transmitted diseases surveillance 2016. Centers for Disease Control and Prevention, Atlanta, GA. .
    1. European Centre for Disease Prevention and Control. 2016. Annual epidemiological report 2016. Gonorrhea. European Centre for Disease Prevention and Control, Stockholm, Sweden: .
    1. Unemo M, Shafer WM. 2014. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 27:587–613. doi:10.1128/CMR.00010-14.
    1. Wi T, Lahra MM, Ndowa F, Bala M, Dillon JR, Ramon-Pardo P, Eremin SR, Bolan G, Unemo M. 2017. Antimicrobial resistance in Neisseria gonorrhoeae: global surveillance and a call for international collaborative action. PLoS Med 14:e1002344. doi:10.1371/journal.pmed.1002344.
    1. Alirol E, Wi TE, Bala M, Bazzo ML, Chen X-S, Deal C, Dillon JR, Kularatne R, Heim J, Hooft van Huijsduijnen R, Hook EW, Lahra MM, Lewis DA, Ndowa F, Shafer WM, Tayler L, Workowski K, Unemo M, Balasegaram M. 2017. Multidrug-resistant gonorrhea: a research and development roadmap to discover new medicines. PLoS Med 14:e1002366. doi:10.1371/journal.pmed.1002366.
    1. Centers for Disease Control and Prevention. 2013. Gonorrhea treatment guidelines: revised guidelines to preserve last effective treatment option. Centers for Disease Control and Prevention, Atlanta, GA. .
    1. World Health Organization. 2017. Global priority list of antibiotic resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization, Geneva, Switzerland. .
    1. Unemo M, Bradshaw CS, Hocking JS, de Vries HJC, Francis SC, Mabey D, Marrazzo JM, Sonder GJB, Schwebke JR, Hoornenborg E, Peeling RW, Philip SS, Low N, Fairley CK. 2017. Sexually transmitted infections: challenges ahead. Lancet Infect Dis 17:e235–e279. doi:10.1016/S1473-3099(17)30310-9.
    1. Suay-García B, Pérez-Gracia MT. 2017. Drug-resistant Neisseria gonorrhoeae: latest developments. Eur J Clin Microbiol Infect Dis 36:1065–1071. doi:10.1007/s10096-017-2931-x.
    1. Unemo M, del Rio C, Shafer WM. 2016. Antimicrobial resistance expressed by Neisseria gonorrhoeae: a major global public health problem in the 21st century. Microbiol Spectr 4:ei10-0009-2015. doi:10.1128/microbiolspec.EI10-0009-2015.
    1. Bax BD, Chan PF, Eggleston DS, Fosberry A, Gentry DR, Gorrec F, Giordano I, Hann MM, Hennessy A, Hibbs M, Huang J, Jones E, Jones J, Brown KK, Lewis CJ, May EW, Saunders MR, Singh O, Spitzfaden CE, Shen C, Shillings A, Theobald AJ, Wohlkonig A, Pearson ND, Gwynn MN. 2010. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466:935–940. doi:10.1038/nature09197.
    1. Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, Sahm DF. 2016. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother 60:1918–1923. doi:10.1128/AAC.02820-15.
    1. Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK. 2017. In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae. Antimicrob Agents Chemother 61:e02047-16. doi:10.1128/AAC.02047-16.
    1. Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, Perry CR, Raychaudhuri A, Scangarella-Oman NE, Hossain M, Dumont EF. 2018. Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2 dose-ranging, single-oral dose evaluation. Clin Infect Dis 67:504–512. doi:10.1093/cid/ciy145.
    1. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano GL. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore. Clin Infect Dis 44:79–86. doi:10.1086/510079.
    1. Bulik CC, Bader JC, Zhang L, Van Wart SA, Rubino CM, Bhavnani SM, Sweeney KL, Ambrose PG. 2017. PK-PD compass: bridging infectious diseases pharmacometrics to the patient’s bedside. J Pharmacokinet Pharmacodyn 44:161–177. doi:10.1007/s10928-017-9518-0.
    1. Nielsen EI, Cars O, Friberg LE. 2011. Pharmacokinetic/pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 55:4619–4630. doi:10.1128/AAC.00182-11.
    1. Clinical and Laboratory Standards Institute. 2016. Development of in vitro susceptibility testing criteria and quality control parameters, 4th ed Document M23 Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Hossain M, Tiffany CA, Day LA, Dumont EF. 2013. Population pharmacokinetic modeling of first-time-in-human data of GSK2140944, a novel antimicrobial compound. Abstr 53rd Intersci Conf Antimicrob Agents and Chemother, abstr F-1217.
    1. Bulik CC, Okusanya ÓO, Lakota EA, Forrest A, Bhavnani SM, Hoover JL, Andes DR, Ambrose PG. 2017. Pharmacokinetic-pharmacodynamic evaluation of gepotidacin against Gram-positive organisms using data from murine infection models. Antimicrob Agents Chemother 61:e00115-16. doi:10.1128/AAC.00115-16.
    1. Jerse AE, Wu H, Packiam M, Vonck RA, Begum AA, Garvin LE. 2011. Estradiol-treated female mice as surrogate hosts for Neisseria gonorrhoeae genital tract infections. Front Microbiol 2:107. doi:10.3389/fmicb.2011.00107.
    1. Scangarella-Oman NE, Dixon P, Koeth LM, DiFranco-Fisher J, Miller LA. 2016. Analysis of agar dilution MIC testing methods and variables and in vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae, poster Sunday-462. ASM Microbe, Boston, MA, 16 to 20 June 2016.
    1. Rice PA, Shafer WM, Ram S, Jerse AE. 2017. Neisseria gonorrhoeae: drug resistance, mouse models, and vaccine development. Annu Rev Microbiol 71:665–686. doi:10.1146/annurev-micro-090816-093530.
    1. Dewi BE, Akira S, Hayashi H, Ba-Thein W. 2004. High occurrence of simultaneous mutations in target enzymes and MtrRCDE efflux system in quinolone-resistant Neisseria gonorrhoeae. Sex Transm Dis 31:353–359. doi:10.1097/00007435-200406000-00007.
    1. O’Riordan W, Tiffany C, Scangarella-Oman N, Perry C, Hossain M, Ashton T, Dumont E. 2017. Efficacy, safety, and tolerability of gepotidacin (GSK2140944) in the treatment of patients with suspected or confirmed gram-positive acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 61:e02095-16. doi:10.1128/AAC.02095-16.
    1. Hossain M, Tiffany CA, McDonald M, Dumont EF. 2014. Safety and pharmacokinetic of repeat escalating oral doses of GSK2140944, a novel bacterial topoisomerase inhibitor, abstr 2320. Abstr 54th Intersci Conf Antimicrob Agents and Chemother.
    1. Jacobsson S, Golparian D, Scangarella-Oman N, Unemo M. 2018. In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae. J Antimicrob Chemother 73:2072–2077. doi:10.1093/jac/dky162.
    1. Garcia LS, Isenberg HD (ed). 2010. Clinical microbiology procedures handbook, 3rd ed ASM Press, Washington, DC.
    1. Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed Document M07-A10 Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing, 27th ed Document M100-S27 Clinical and Laboratory Standards Institute, Wayne, PA.
    1. Gonococcal Isolate Surveillance Program. 2016. Protocol. Centers for Disease Control and Prevention, Atlanta, GA. .
    1. Vernel-Pauillac F, Hogan TR, Tapsall JW, Goarant C. 2009. Quinolone resistance in Neisseria gonorrhoeae: rapid genotyping of quinolone resistance-determining regions in gyrA and parC genes by melting curve analysis predicts susceptibility. Antimicrob Agents Chemother 53:1264–1267. doi:10.1128/AAC.01104-08.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅